Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials show Ozempic (semaglutide) produces weight loss ranging from 10–15% of baseline body weight over 68 weeks, with some patients achieving greater reductions. However, these averages mask substantial individual variation, driven by genetics, adherence, diet quality, and baseline metabolic health.

For patients considering semaglutide or other GLP-1 receptor agonists, understanding what drives these differences matters. PlexusDx takes a precision-wellness approach: assessing not just medication options but the biomarker and genetic context that may help predict individual response patterns and support more informed treatment planning with your provider.

Published Weight Loss Data from Ozempic Clinical Trials

The SUSTAIN trials—the pivotal evidence base for Ozempic—tracked weight loss in adults with type 2 diabetes over 68 weeks. Participants on 1.0 mg weekly semaglutide lost approximately 3.7 kg (8 lbs); those on 1.0 mg achieved roughly 5.1 kg (11 lbs); the 1.0 mg dose produced an average 5.7 kg (12.5 lbs) loss relative to placebo.

More recent data from the STEP trials—which enrolled individuals without diabetes seeking weight loss—documented mean reductions of 9.4–12.4% of baseline weight depending on dose and study duration. These numbers represent averages. Real-world variation is substantial, with some patients losing 20%+ and others experiencing minimal change despite consistent adherence.

Biological and Behavioral Factors That Influence Individual Outcomes

Weight loss response depends on multiple overlapping factors: GLP-1 receptor sensitivity (partly genetically determined), baseline insulin resistance, body composition, diet quality, physical activity, sleep, and medication adherence. No single factor predicts outcome with certainty. Instead, a constellation of biomarkers—including fasting glucose, insulin, triglycerides, and inflammatory markers—provides context.

Genetic variants in GLP1R, GIPR, MC4R, and FTO genes are associated with differential appetite, satiety signaling, and metabolic rate. These are predispositions, not deterministic: environmental factors and behavioral choices remain critical. A patient with favorable genetic variants who eats processed foods and skips exercise may lose less weight than someone with less favorable genetics who prioritizes nutrition and movement.

Factor Category Impact on Weight Loss Outcomes
GLP-1 Receptor Function Genetic variants (rs6923761) may influence receptor sensitivity and appetite suppression effectiveness
Baseline Metabolic Health Higher baseline insulin resistance often correlates with greater weight loss potential on GLP-1 therapy
Diet Quality and Adherence Calorie intake, macronutrient balance, and consistency of dietary choices determine net energy deficit
Physical Activity and Sleep Regular movement and 7–9 hours nightly sleep support metabolic health and medication efficacy
Baseline Body Weight and BMI Patients with higher baseline BMI may lose more absolute pounds but similar percentages as those with lower BMI

Why Percent Weight Loss Matters More Than Absolute Numbers

A patient weighing 300 lbs losing 40 lbs (13.3%) and a 200 lb patient losing 20 lbs (10%) both experience meaningful metabolic improvements, despite different absolute losses. Clinically, 5–10% weight reduction improves insulin sensitivity, lipid profiles, and cardiovascular markers. Greater reductions (15%+) correlate with additional metabolic and joint benefits.

Setting expectations around percentage loss—rather than a specific target weight—is medically prudent. Combined with lifestyle measures (structured eating, movement, sleep), consistent GLP-1 therapy typically produces 10–20% reductions in most compliant patients. Outcomes below or above this range warrant provider reassessment of adherence, diet quality, genetic predispositions, and potential dosing adjustments.

Evaluating Your Individual Predisposition and Treatment Readiness

Before starting semaglutide or any GLP-1 receptor agonist, healthcare providers should establish baseline metabolic health through fasting glucose, insulin, lipids, and inflammatory markers. This baseline serves as a reference for evaluating medication efficacy and identifying metabolic patterns that might inform dose timing, dietary modifications, or complementary interventions.

Genetic testing for peptide pathway predispositions (GLP1R, GIPR, MC4R, FTO variants) may help contextualize why certain patients respond robustly while others require higher doses or adjunctive strategies. This information should never replace clinical evaluation but can support more personalized conversations with your provider about realistic outcomes and individualized treatment adjustments over time.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key peptide pathway genes—including GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—that may help provide context for how an individual's metabolism and appetite signaling respond to GLP-1 therapy. These variants influence receptor sensitivity, metabolic rate, and satiety mechanisms.

The genetic test does not predict exact medication response or guarantee weight loss outcomes. Rather, it identifies predispositions in appetite regulation, energy expenditure, and metabolic flexibility that should be interpreted with a qualified healthcare provider. Combined with biomarker assessment (fasting insulin, glucose, inflammatory markers), this information helps build a more complete picture of individual metabolic context.

Understanding your genetic predispositions and metabolic baseline can support a more informed conversation with your provider about realistic weight loss expectations, optimal dosing strategies, dietary modifications, and whether compounded GLP-1 options (semaglutide, tirzepatide, or dual GLP-Squared compounds) align with your health profile and goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves